Colitis as a manifestation of infliximab-associated disseminated cryptococcosis

International Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages e436-e440

  Osawa, Ryosuke ^a   Singh, Nina ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Crohn's disease; Cryptococcosis; Cryptococcus; Gastrointestinal diseases; Tumor necrosis factor inhibitors

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; BONE BIOPSY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GOLD STANDARD; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OSTEOMYELITIS; PREDICTIVE VALIDITY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINUS TRACT CULTURE; SKIN FISTULA;

EID: 84859601793     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.05.019     Document Type: Article

References (52)

1. Chayakulkeeree M., Perfect J.R. Cryptococcosis. Infect Dis Clin North Am 2006, 20:507-544.
2. Jarvis J.N., Harrison T.S. HIV-associated cryptococcal meningitis. AIDS 2007, 21:2119-2129.
3. Singh N., Dromer F., Perfect J.R., Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008, 47:1321-1327.
4. Perfect J.R., Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002, 16:837-874.
5. Dromer F., Mathoulin-Pelissier S., Fontanet A., Ronin O., Dupont B., Lortholary O. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004, 18:555-562.
6. Mirza S.A., Phelan M., Rimland D., Graviss E., Hamill R., Brandt M.E., et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789-794.
7. Muñoz P., Giannella M., Valerio M., Soria T., Díaz F., Longo J.L., et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 2007, 57:443-446.
8. Tsiodras S., Samonis G., Boumpas D.T., Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-194.
9. Perfect J.R. Cryptococcosis. Infect Dis Clin North Am 1989, 3:77-102.
10. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
11. Albert-Braun S., Venema F., Bausch J., Hunfeld K.P., Schäfer V. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection 2005, 33:282-288.
12. Singh C.S., Rahman M., Jamil S., Sawhney H., Vernaleo J., Thelmo W. Cholecystitis as the initial manifestation of disseminated cryptococcosis. AIDS 2007, 21:2111-2112.
13. Singh N., Husain S., De Vera M., Gayowski T., Cacciarelli T.V. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 2004, 83:188-192.
14. Yinnon A.M., Solages A., Treanor J.J. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993, 17:736-741.
15. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007, 195:756-764.
16. Dromer F., Mathoulin S., Dupont B., Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996, 23:82-90.
17. Washington K., Gottfried M.R., Wilson M.L. Gastrointestinal cryptococcosis. Mod Pathol 1991, 4:707-711.
18. Bonacini M., Nussbaum J., Ahluwalia C. Gastrointestinal, hepatic, and pancreatic involvement with Cryptococcus neoformans in AIDS. J Clin Gastroenterol 1990, 12:295-297.
19. Zelman S., O'Neil R.H., Plaut A. Disseminated visceral torulosis without nervous system involvement with clinical appearance of granulocytic leukemia. Am J Med 1951, 11:658-664.
20. Unat E.K., Pars B., Kosyak J.P. A case of cryptococcosis of the colon. Br Med J 1960, 2:1501-1502.
21. Jacobs D.H., Macher A.M., Handler R., Bennett J.E., Collen M.J., Gallin J.I. Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome. Gastroenterology 1984, 87:201-203.
22. Hutto J.O., Bryan C.S., Greene F.L., White C.J., Gallin J.I. Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome. Gastroenterology 1988, 94:808-812.
23. Van Calck M., Motte S., Rickaert F., Serruys E., Adler M., Wybran J. Cryptococcal anal ulceration in a patient with AIDS. Am J Gastroenterol 1988, 83:1306-1308.
24. Hurd D.D., Staub D.B., Roelofs R.I., Dehner L.P. Profound muscle weakness as the presenting feature of disseminated cryptococcal infection. Rev Infect Dis 1989, 11:970-974.
25. Daly J.S., Porter K.A., Chong F.K., Robillard R.J. Disseminated, nonmeningeal gastrointestinal cryptococcal infection in an HIV-negative patient. Am J Gastroenterol 1990, 85:1421-1424.
26. de Otero J., Flor A., Cortés E., Cuenca A., de Torres I., Capdevilea J.A. Cryptococcal gastrointestinal ulcerations in an HIV-positive patient. Enferm Infecc Microbiol Clin 1994, 12:176-177.
27. Chalasani N., Wilcox C.M., Hunter H.T., Schwartz D.A. Endoscopic features of gastroduodenal cryptococcosis in AIDS. Gastrointest Endosc 1997, 45:315-317.
28. Melato M., Gorji N. Primary intestinal cryptococcosis mimicking adenomatous polyp in an HIV-negative patient. Am J Gastroenterol 1998, 93:1592-1593.
29. Trevenzoli M., Lanzafame M., Lazzarini L., Carretta G., Vento S., Concia E. Esophageal cryptococcosis in a patient with AIDS. Am J Gastroenterol 1999, 94:1981-1982.
30. Molino D., Salvatore De Santo L., Delfino M., Insabato L., Ferraraccio F., Cirillo M., et al. Anasarca caused by Cryptococcus neoformans after heart transplantation. J Heart Lung Transplant 2003, 22:478-483.
31. Chaitowitz M., Shaw M.L., Mokoena T.R. Gastrointestinal cryptococcosis presenting as spontaneous jejunal perforation in a nonimmunocompromised host. Dig Dis Sci 2003, 48:1196-1199.
32. Nawabi D.H., Ffolkes L., O'Bichere A. Cryptococcal small-bowel obstruction in an HIV-positive patient. J R Soc Med 2005, 98:513-514.
33. Law J.K., Amar J.N., Kirby S.D., Zetler P.J., Enns R.A. Colonic cryptococcus infection. Gastrointest Endosc 2007, 65:525-526. discussion 526.
34. Saha S., Agarwal N., Srivastava A., Kumar A. Perforation peritonitis due to gastrointestinal cryptococcosis as an initial presentation in an AIDS patient. Singapore Med J 2008, 49:e305-e307.
35. Song J.C., Kim S.K., Kim E.S., Jung I.S., Song Y.G., Yu J.S., et al. A case of colonic cryptococcosis. Korean J Gastroenterol 2008, 52:255-260.
36. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
37. Wallis R.S., Broder M., Wong J., Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254-1255.
38. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
39. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
40. Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41(Suppl 3):S189-S193.
41. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168:4620-4627.
42. Bekker L.G., Freeman S., Murray P.J., Ryffel B., Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001, 166:6728-6734.
43. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178:2249-2254.
44. Huffnagle G.B., Toews G.B., Burdick M.D., Boyd M.B., McAllister K.S., McDonald R.A., et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996, 157:4529-4536.
45. Safdar A., Rubocki R.J., Horvath J.A., Narayan K.K., Waldron R.L. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002, 35:1250-1257.
46. Singh N., Perfect J.R. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007, 7:395-401.
47. Shelburne S.A., Darcourt J., White A.C., Greenberg S.B., Hamill R.J., Atmar R.L., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:1049-1052.
48. Singh N., Lortholary O., Alexander B.D., Gupta K.L., John G.T., Pursell K., et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005, 40:1756-1761.
49. Arend S.M., Leyten E.M., Franken W.P., Huisman E.M., van Dissel J.T. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007, 45:1470-1475.
50. Garcia Vidal C., Rodríguez Fernández S., Martínez Lacasa J., Salavert M., Vidal R., Rodríguez Carballeira M., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40:756-759.
51. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712.
52. Blackmore T.K., Manning L., Taylor W.J., Wallis R.S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008, 47:e83-e85.